NO2, BC and PM Exposure of Participants in the Polluscope Autumn 2019 Campaign in the Paris Region.

The Polluscope project aims to better understand the personal exposure to air pollutants in the Paris region. This article is based on one campaign from the project, which was conducted in the autumn of 2019 and involved 63 participants equipped with portable sensors (i.e., NO2, BC and PM) for one week. After a phase of data curation, analyses were performed on the results from all participants, as well as on individual participants' data for case studies. A machine learning algorithm was used to allocate the data to different environments (e.g., transportation, indoor, home, office, and outdoor). The results of the campaign showed that the participants' exposure to air pollutants depended very much on their lifestyle and the sources of pollution that may be present in the vicinity. Individuals' use of transportation was found to be associated with higher levels of pollutants, even when the time spent on transport was relatively short. In contrast, homes and offices were environments with the lowest concentrations of pollutants. However, some activities performed in indoor air (e.g., cooking) also showed a high levels of pollution over a relatively short period.

[A selection of advances in neuromuscular medicine]. / Neueste Entwicklungen der Neuromuskulären Medizin.

A selection of advances in neuromuscular medicine Abstract. Significant developments in the realm of neuromuscular medicine have occurred in both non-invasive diagnostics as well as treatments. Whole body muscle MRI can detect disease specific patterns and lead to the implementation of direct molecular genetic diagnostics. Bedside neuromuscular ultrasound can assist in diagnosing inflammatory neuropathies even in some cases enabling the omission of nerve biopsy and lumbar puncture. Specific antibodies aid in the classification and management of acquired autoimmune diseases. First effective genetic therapies for monogenetic neuromuscular illnesses are now available for spinal muscular atrophy and familial transthyretin amyloidosis. This overview aims to highlight select new diagnostic and therapeutic achievements in the realm of neuromuscular medicine.